GIST Exon gesteuerte Therapie adjuvant/palliativ
|
|
- Edmund Kennedy
- 6 years ago
- Views:
Transcription
1 GIST Exon gesteuerte Therapie adjuvant/palliativ Peter Reichardt HELIOS Klinikum Bad Saarow / Sarkomzentrum Berlin-Brandenburg
2 Offenlegung potentieller Interessenkonflikte 1. Anstellungsverhältnis oder Führungsposition keine 2. Beratungstätigkeit Novartis, Pfizer, PharmaMar, Bayer 3. Aktienbesitz keiner 4. Honorare Novartis, Pfizer, PharmaMar 5. Finanzierung wissenschaftlicher Untersuchungen Novartis 6. Gutachtertätigkeit keine 7. Andere finanzielle Beziehungen keine
3 Adjuvant Imatinib Therapy for GIST: Rationale >50% risk of recurrence after resection in patients with high-risk GIST Imatinib represents effective oral therapy with a low toxicity profile and may be effective as an adjuvant to surgery in Treatment of low-volume microscopic disease Trials investigating use of imatinib in an adjuvant setting Randomized: ACOSOG Z9001 SSGXVIII EORTC Non-randomized: ACOSOG Z9000 Korean trial Chinese trial
4 Z9001: Recurrence-Free Survival DeMatteo et al. Lancet. 2009;373:
5 Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala, P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt, J Clin Oncol 29: 2011 (suppl; abstr LBA1) Random Assignment 1:1 Imatinib for 12 months Follow-up Strata: 1) R0 resection, no tumor spillage 2) spillage or R1 resection Imatinib for 36 months Follow-up
6 Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala, P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt, J Clin Oncol 29: 2011 (suppl; abstr LBA1) Study endpoints: Primary: recurrence-free survival (RFS) Time from randomization to GIST recurrence or death; second cancer not considered Secondary: Safety Overall survival (OS) GIST-specific survival
7 Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala, P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt, J Clin Oncol 29: 2011 (suppl; abstr LBA1) Key inclusion criteria: Histologically confirmed KIT-positive GIST High risk of recurrence according to the modified Consensus Criteria: Tumor size >10 cm or Tumor mitosis count >10 /50 HPF or Size >5 cm and mitosis count >5/50 HPFs or Tumor rupture spontaneously or at surgery
8 Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala, P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt, J Clin Oncol 29: 2011 (suppl; abstr LBA1) Recurrence-free survival (RFS) % % 60.1% 65.6% 47.9% 36 Months of imatinib 12 Months of imatinib 20 0 Hazard ratio 0.46 (95% CI, ) P < Years since randomization
9 Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala, P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt, J Clin Oncol 29: 2011 (suppl; abstr LBA1) Overall survival (ITT) % % 94.0% 92.0% 81.7% Months of imatinib 12 Months of imatinib Hazard ratio 0.45 (95% CI, ) P = Years since randomization
10 Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) M. von Mehren et al., J Clin Oncol 29: 2011 (suppl; abstr 10016)
11 Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) M. von Mehren et al., J Clin Oncol 29: 2011 (suppl; abstr 10016)
12 Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) M. von Mehren et al., J Clin Oncol 29: 2011 (suppl; abstr 10016)
13 Sorafenib Reichardt et al., J Clin Oncol 27:15s, 2009 (suppl; abstr 10564)
14 Sorafenib in patients with imatinib and sunitinib-resistant gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial H. L. Kindler et al., J Clin Oncol 29: 2011 (suppl; abstr 10009)
15 A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study M. Ryu et al., J Clin Oncol 29: 2011 (suppl; abstr 10010)
16 A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study M. Ryu et al., J Clin Oncol 29: 2011 (suppl; abstr 10010)
17 A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study M. Ryu et al., J Clin Oncol 29: 2011 (suppl; abstr 10010)
18 A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib and sunitinib S. George et al., J Clin Oncol 29: 2011 (suppl; abstr 10007)
19 A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib and sunitinib S. George et al., J Clin Oncol 29: 2011 (suppl; abstr 10007)
20 A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib and sunitinib S. George et al., J Clin Oncol 29: 2011 (suppl; abstr 10007)
21 A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib and sunitinib S. George et al., J Clin Oncol 29: 2011 (suppl; abstr 10007)
22 A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib and sunitinib S. George et al., J Clin Oncol 29: 2011 (suppl; abstr 10007)
Long Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationRisk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
https://helda.helsinki.fi Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib Joensuu, Heikki 2014-08-01 Joensuu, H, Eriksson, M, Hall, K S, Hartmann,
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Adjuvant imatinib after complete resection of primary gastrointestinal stromal tumour (GIST) in patients at high risk of relapse May 2012 Summary NICE guidance
More informationOne vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. Trial Registration clinicaltrials.gov Identifier: NCT
ORIGINAL CONTRIBUTION One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Heikki Joensuu, MD Mikael Eriksson, MD Kirsten Sundby Hall, MD Jörg T. Hartmann,
More informationSupplementary Online Content
Supplementary Online Content Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an
More informationJ Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 3 JANUARY 20, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial Heikki Joensuu, Mikael Eriksson,
More informationOptimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression
The Oncologist Gastrointestinal Cancer Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression AXEL LE CESNE, a JEAN-YVES
More informationESMO Consensus Empfehlungen 2017
ESMO Consensus Empfehlungen 2017 What s old, what s new, what s missing? Jörg Beyer, Klinik für Onkologie Offenlegung Interessenskonflikte 1. Anstellungsverhältnis oder Führungsposition Keine 2. Beratungs-
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Imatinib (Glivec ) 100 mg and 400 mg film-coated tablets. Reference number: 1653 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Imatinib (Glivec ) 100 mg and 400 mg film-coated tablets Reference number: 1653 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics and Toxicology
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
GIST (Gastrointestinal stromal tumor) Updated MARCH 2017 by Dr. Doreen Ezeife, PGY-5 Resident, University of Calgary Reviewed by Dr. Jan-Willem Henning (Staff Medical Oncologist, University of Calgary)
More informationPrimary gastrointestinal stromal tumor of the liver treated with sequential therapy
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v21.i8.2573 World J Gastroenterol 2015 February 28; 21(8): 2573-2576 ISSN 1007-9327
More informationNuevos avances en el tratamiento de los GIST
Nuevos avances en el tratamiento de los GIST Dr Javier Martin Broto Oncología Médica HospitalSon Espases Palma de Mallorca www.cotmes.com AGENDA Enfermedad localizada SSG AIO Enfermedad diseminada Sorafenib
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationGastrointestinal stromal tumors (GIST)
Gastrointestinal stromal tumors (GIST) JY Blay Professor of Medicine GIST : standard of care Nosology : not a single disease Treatment of localized GIST Adjuvant treatment Treatment of advanced GIST First
More informationAnalysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
Ann Surg Oncol DOI 10.1245/s10434-014-3632-7 ORIGINAL ARTICLE BONE AND SOFT TISSUE SARCOMAS Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy
More informationYasumasa MONOBE 1), Yoshio NAOMOTO 2), Jiro HAYASHI 2), Tomoki YAMATSUJI 2), Yoshito SADAHIRA 3)
Kawasaki Medical Journal 43(1):5 12,2017 doi:10.11482/kmj-e43(1)5 5 Case Report A case of gastrointestinal stromal tumor (GIST) with peritoneal dissemination - Imatinib re-challenged case - Yasumasa MONOBE
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations Summary Date prepared: May 2012 Imatinib was the first
More informationFollow-up in soft tissue sarcomas
memo (2014) 7:92 96 DOI 10.1007/s12254-014-0146-8 Follow-up in soft tissue sarcomas Piotr Rutkowski Iwona Ługowska Received: 8 February 2014 / Accepted: 19 May 2014 / Published online: 13 June 2014 The
More informationOriginal Article. Keywords: Gastrointestinal stromal tumors (GIST); KIT; tyrosine kinase inhibitors (TKIs); immunohistochemical staining
Original Article Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico Abdel Karim Dip Borunda,
More informationCase Report Huge gastrointestinal stromal tumor with peritoneal metastasis: a case report
Int J Clin Exp Med 2017;10(9):13868-13873 www.ijcem.com /ISSN:1940-5901/IJCEM0057829 Case Report Huge gastrointestinal stromal tumor with peritoneal metastasis: a case report Wei Ding *, Yulin Tan *, Jianguo
More informationGiant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib
Int Canc Conf J (2012) 1:41 46 DOI 10.1007/s13691-011-0007-9 CASE REPORT Giant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib Kaori Shigemitsu Takako Yamada Shinichiro
More informationA systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour
ORIGINAL ARTICLE NETWORK META-ANALYSIS OF POST-IMATINIB THERAPY IN ADVANCED GIST, Shah et al. A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal
More informationDNMT- and HDAC-inhibitors globally induce cryptic transcription start sites encoded in long terminal repeats
DNMT- and HDAC-inhibitors globally induce cryptic transcription start sites encoded in long terminal repeats DGHO Jahrestagung, 29.09.-03.10.2017 Stuttgart Germany Michael Daskalakis of Epigenomics and
More informationExtended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors
Mol Diagn Ther (2013) 17:9 19 DOI 10.1007/s40291-013-0018-7 CURRENT OPINION Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors Recommendations for Patient Selection,
More informationPatient Management Policy
London and South East Patient Management Policy This document has been compiled by members of the London and South East and approved by all consultants. It will be reviewed and updated annually. The purpose
More informationGastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 23 (Supplement 7): vii49 vii55, 2012 doi:10.1093/annonc/mds252 Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up The ESMO / European
More informationImatinib Therapy - GIST
INDICATIONS FOR USE: Imatinib Therapy - GIST Regimen Code INDICATION ICD10 Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours
More informationJY Blay. New horizons 2011
Prevention of GIST resistance JY Blay Medical Oncology Chairman of the Soft Tissue and Bone Sarcoma Group of EORTC Chairman of the CONTICANET Network of Excellence 6th Framework Program of the European
More informationEfficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v18.i7.698 World J Gastroenterol 2012 February 21; 18(7): 698-703 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationBosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the BFORE Trial
Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the BFORE Trial Tim H. Brümmendorf, 1 Carlo Gambacorti-Passerini, 2 Michael Deininger, 3 Michael J. Mauro, 4 Charles Chuah,
More informationTherapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs?
Editorial Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs? Toshirou Nishida Department of Surgery, National Cancer Center Hospital,
More informationRetrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor
/, 2017, Vol. 8, (No. 6), pp: 10136-10144 Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor Yang Fu 1,*, He Hao 1,*, Luwei Guo 1, Ge Yang 2, Xiefu Zhang 1 1 Department
More informationOverview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib)
Overview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib) George D. Demetri, M.D. Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Harvard Medical School
More informationM.D., M.H.S., F.A.C.P.
2011 GASCO Highlights GI Oncology Michael Morse, M.D., M.H.S., F.A.C.P. Associate Professor, GI Oncology Duke University Medical Center Discussion Points GIST Plenary session highlights Hepatocellular
More informationPharmacological treatment of gastrointestinal stromal tumors: update from recent clinical trials
Review: Clinical Trial Outcomes Pharmacological treatment of gastrointestinal stromal tumors: update from recent clinical trials Clin. Invest. (2012) 2(5), 537 544 Gastrointestinal stromal tumors (GISTs)
More informationAnnals of Oncology Advance Access published February 2, 2011
Advance Access published February 2, 2011 original article doi:10.1093/annonc/mdq696 Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal
More informationFlorence Duffaud 1-3, Axel Le Cesne 4
REVIEW Recent advances in managing gastrointestinal stromal tumor [version 1; referees: 2 approved] Florence Duffaud 1-3, Axel Le Cesne 4 1Service d Oncologie Médicale, CHU La Timone, Marseille, France
More informationCan Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
Review Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST? IVAR HOMPLAND 1 and ØYVIND S. BRULAND 1,2 1 Department of Oncology, Oslo University Hospital, Norwegian Radium
More informationEvaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment
The Open Pathology Journal, 2009, 3, 53-57 53 Open Access Evaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment Katie L. Dennis * and Ivan Damjanov Department of Pathology
More informationClinical Study Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial
International Surgical Oncology Volume 2012, Article ID 761576, 8 pages doi:10.1155/2012/761576 Clinical Study Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal
More informationJMSCR Vol 06 Issue 06 Page June 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i6.43 Emergency Presentation and Management
More informationClinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
Yeh et al. World Journal of Surgical Oncology 2012, 10:246 WORLD JOURNAL OF SURGICAL ONCOLOGY REVIEW Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan Open Access
More informationNexavar. Nexavar (sorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.60 Section: Prescription Drugs Effective Date: July 1,2017 Subject: Nexavar Page: 1 of 5 Last Review
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationABSTRACT. Clinical Research Paper
/, 2017, Vol. 8, (No. 41), pp: 71128-71137 Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
More informationThe Clinical Approach to Wild Type GIST. Margaret von Mehren, MD Professor and Director of Sarcoma Oncology Fox Chase Cancer Center
The Clinical Approach to Wild Type GIST Margaret von Mehren, MD Professor and Director of Sarcoma Oncology Fox Chase Cancer Center Disclosure slide Scientific Advisor to Novartis, Pfizer, Merck Research
More informationManaging adult soft tissue sarcomas and gastrointestinal stromal tumours
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationAsian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines
Review Article Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines Toshirou Nishida Department of Surgery, National Cancer Center
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and
More informationSLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
FULL PAPER British Journal of Cancer (217) 116, 1195 122 doi: 1.138/bjc.217.82 Keywords: gastrointestinal stromal tumour; SLUG; SNAI2; survival; proliferation; apoptosis SLUG transcription factor: a pro-survival
More informationGIST: imatinib and beyond
GIST: imatinib and beyond Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick Schoffski 4, Sebastian Bauer 5,
More informationPathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib
1424 Molecular Insights in Patient Care Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib Joshua B. Brown, MD, MSc a ; Reetesh
More informationDrug-drug interactions with oncolytics (in particular PPIs and TKIs)
Drug-drug interactions with oncolytics (in particular PPIs and TKIs) Prof. Ron Mathijssen, MD PhD Medical Oncologist/ Clinical Pharmacologist Erasmus MC Cancer Institute Rotterdam ICPAD Workshop November
More informationArticles. Funding Bayer HealthCare Pharmaceuticals.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationC-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach
pissn : 2093-582X, eissn : 2093-5641 J Gastric Cancer 2015;15(4):290-294 http://dx.doi.org/10.5230/jgc.2015.15.4.290 Case Report C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach Ho Seok Seo,
More informationStivarga. Stivarga (regorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationA CASE REPORT ON GASTROINTESTINAL STROMAL TUMOR(GISTs)
A CASE REPORT ON GASTROINTESTINAL STROMAL TUMOR(GISTs) Khan Farhan 1*, Dareka Khizra Mushtaq 2, Chaurasiya Rabindra 3, Yadav Priyam 4, Adhikari Bivek 5, Yadav Kapil Dev 6 and Vaidya Rajan 7 1 Department
More informationNew and Emerging Therapies for Soft Tissue Sarcomas and GIST: Recent Clinical Data and Expert Recommendations
New and Emerging Therapies for Soft Tissue Sarcomas and GIST: Recent Clinical Data and Expert Recommendations George D. Demetri, M.D. Director, Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute
More informationUpdate on Gastrointestinal Stromal Tumors for Radiologists
Review Article Cancer Imaging https://doi.org/10.3348/kjr.2017.18.1.84 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2017;18(1):84-93 Update on Gastrointestinal Stromal Tumors for Radiologists Sree Harsha
More informationPreoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
Tang et al. World Journal of Surgical Oncology (2017) 15:79 DOI 10.1186/s12957-017-1143-2 RESEARCH Open Access Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST) Sumin
More informationBernd Kasper 1, Viktor Grünwald 2, Peter Reichardt 3, Sebastian Bauer 4, Florian Haller 5, Peter Hohenberger 1
Clinical and translational research results of a phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors - a study of the German Interdisciplinary Sarcoma Group
More informationClinicopathologic, surgical characteristics and survival outcomes of rectal gastrointestinal stromal tumors
610 Neoplasma 62, 4, 2015 doi:10.4149/neo_2015_073 Clinicopathologic, surgical characteristics and survival outcomes of rectal gastrointestinal stromal tumors C. SHEN 1, H. CHEN 1, R. YIN 2, Y. YIN 1,
More informationAdjuvant Imatinib for High Risk Gastrointestinal Stromal Tumor: An Analysis of a Randomized Trial
Adjuvant Imatinib for High Risk Gastrointestinal Stromal Tumor: An Analysis of a Randomized Trial Joensuu, et al DOI: 10.1200/JCO.2015.62.9170 The information provided may not reflect the complete protocol
More informationPerioperative Treatment of Gastrointestinal Stromal Tumors
Review Article [1] January 01, 2009 By Gustavo Dos Santos Fernandes, MD [2], Charles D. Blanke, MD, FACP [3], Daniela Freitas, MD [4], Rodrigo Guedes, MD [5], and Paulo M. Hoff, MD, FACP [6] Gastrointestinal
More informationNeoadjuvant therapy for gastrointestinal stromal tumor
Review Article Neoadjuvant therapy for gastrointestinal stromal tumor Takashi Ishikawa 1, Tatsuo Kanda 2, Hitoshi Kameyama 1, Toshifumi Wakai 1 1 Division of Digestive and General Surgery, Niigata University
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Gastrointestinal Stromal Tumors
pan-canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Gastrointestinal Stromal Tumors May 2, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationClinical Trials. Phase II Studies. Connective Tissue Oncology Society. Jon Trent, MD, PhD
Clinical Trials Phase II Studies Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center Connective Tissue Oncology Society GIST Overview
More informationAsian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(4):1155-1166 Special Article http://dx.doi.org/10.4143/crt.2016.187 Open Access Asian Consensus Guidelines for the Diagnosis and Management of
More informationSurgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy
Sugase et al. Surgical Case Reports (2016) 2:137 DOI 10.1186/s40792-016-0266-y CASE REPORT Open Access Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib
More informationDCC-2618, a novel pan-kit and PDGFR
DCC-2618, a novel pan-kit and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST) N. Somaiah, A. Razak, M. Gordon, F.
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 5, Issue 1 2015 Article 3 Laparoscopic Assisted Resection Of Large Rectal GIST Is Safe And Oncological Feasible: A Case Report And Review Of The Literature Daniel
More informationGastrointestinal Stromal Tumor Surgery and Adjuvant Therapy
Gastrointestinal Stromal Tumor Surgery and Adjuvant Therapy Valerie P. Grignol, MD a, Paula M. Termuhlen, MD b, * KEYWORDS GIST Gastrointestinal stromal tumor KIT PDGFRA Imatinib mesylate Gastrointestinal
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationAdjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Ronald P DeMatteo, Karla V Ballman, Cristina R Antonescu,
More informationClinicopathological features and prognosis of small gastrointestinal stromal tumors outside the stomach
ONCOLOGY LETTERS 10: 2723-2730, 2015 Clinicopathological features and prognosis of small gastrointestinal stromal tumors outside the stomach YONG PENG WANG 1, YI LI 2 and CHUN SONG 1 Departments of 1 Colorectal
More informationNew Horizons 2018 Vienna, Austria
New Horizons 2018 Vienna, Austria Salud con Datos aims to gather representatives from disease advocacy organizations, medical professionals, industry representatives to discuss data sharing and data utilization
More informationManagement of gastrointestinal stromal tumors: Five years period, Tanta experience.
Management of gastrointestinal stromal tumors: Five years period, Tanta experience Mohamed El-Shebiney 1, Alaa Maria 1 and Emad Sadaka 1 and Ayman El-Namer 2 1 Clinical Oncology department, Faculty of
More informationMicroscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence Martin D McCarter, MD, FACS, Cristina R Antonescu, MD, Karla V Ballman, PhD,
More informationGastrointestinal Stromal Tumor Case Presentations
Gastrointestinal Stromal Tumor Case Presentations Ricardo J. Gonzalez, MD Professor of Surgery Chair, Sarcoma Department Chief of Surgery Moffitt Cancer Center Patient number 1 64 yo male with upper abdominal
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 5 Last Review Date: September 15, 2017 Sutent Description Sutent (sunitinib)
More informationA randomized phase III study. Scandinavian Sarcoma Group and Sarcoma Group of the AIO, Germany
Scandinavian Sarcoma Group and Sarcoma Group of the AIO, Germany Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable
More informationMonday, 5 February 2018
Educational sessions for Junior audience Monday, 5 February 2018 09:30-11:00 Session 1 The diseases Chairs: Paolo. G Casali, IT; Paula Collini, IT 25 The natural history of STS & GIST Paolo. G Casali,
More informationNeoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum
Kyo et al. World Journal of Surgical Oncology (2016) 14:68 DOI 10.1186/s12957-016-0837-1 CASE REPORT Open Access Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)
More informationEncouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST)
2017 ESMO Proffered Paper Encouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST) F Janku, A Razak, M Gordon, D Flynn, M Kaufman,
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial The Harvard community has
More informationResponse to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
DOI 10.1186/s13569-015-0036-9 CLINICAL SARCOMA RESEARCH CASE REPORT Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation Andrew S. Brohl 1*, Elizabeth G. Demicco
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationKey Words. Imatinib Gleevec KIT CD117 Gastrointestinal stromal tumors
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationTargeted Therapy for Gastrointestinal Stromal Tumor: Emerging concepts in oncogenetics and therapy sequencing
Targeted Therapy for Gastrointestinal Stromal Tumor: Emerging concepts in oncogenetics and therapy sequencing Lesly A. Dossett 1, Mihaela Druta 1, and Ricardo J. Gonzalez 1* 1 Sarcoma Department, Moffitt
More informationDay 1: ESMO Sarcoma & GIST Faculty closed meeting
Day 1: ESMO Sarcoma & GIST Faculty closed meeting Sunday, 4 February 2018 12:30 14:00 Lunch 14:00-16:00 Discussion: Should we routinely use NGS? 120 Panel discussion 16:00 16:30 Coffee Break 16:30-18:00
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Malignant Gastrointestinal Stromal tumor of the Sigmoid Colon with Perforation and Peritonitis - an Unusual
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationGastrointestinal Stromal Tumors: challenges in diagnosis and treatment
Gastrointestinal Stromal Tumors: challenges in diagnosis and treatment Waleed Hammam Mosa (1) Abdelmoiem Mourad (2) Reem Ashery (2) Ibrahim Abdelkader Salama (3) (1) Department of Clinical Oncology, Faculty
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More information